Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Subscribe
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Securities and Exchange Commission
Health Tech
Hims & Hers downplays business impact of compounded GLP-1s
Hims & Hers is also facing an investigation from the Securities and Exchange Commission, as revealed in a regulatory filing earlier this week.
Heather Landi
Feb 25, 2026 1:30pm
Humana: 20% of members in MA plans with 4-plus stars for 2026
Oct 2, 2025 4:49pm
UnitedHealth rises on positive MA star ratings outlook
Sep 9, 2025 11:00am
UnitedHealth forms board committee aimed at greater oversight
Aug 21, 2025 12:19pm
Omada Health raises $150M in IPO
Jun 6, 2025 7:00am
Hinge Health prices IPO at $32 per share
May 21, 2025 7:00pm
